Related Experiment Video
Updated: Jul 17, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation
Lecia V Sequist1, Victoria A Joshi, Pasi A Jänne
1Massachusetts General Hospital Cancer Center, Harvard Medical School/Partners HealthCare Center for Genetics and Genomics, MGH Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts 02114, USA. lvsequist@partners.org
Abstract:
Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with clinical response and prolonged survival in patients with non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). We began screening patients for somatic EGFR mutations by DNA sequencing as part of clinical care in 2004. We performed a retrospective cohort study of 278 patients with NSCLC referred for EGFR testing over a 10-month period. Tumor samples underwent direct DNA sequence analyses of EGFR exons 18 through 24. We determined the clinical characteristics and EGFR mutation status of the patients and analyzed their response to therapy and survival. EGFR somatic mutations were identified in 68 (24%) of patients. A minimal smoking history was the strongest clinical predictor of harboring a mutation. In multivariable analyses, each pack-year of smoking corresponded to a 5% decreased likelihood of having an EGFR mutation. Among 92 patients with unresectable disease undergoing subsequent systemic therapy, EGFR mutations were associated with an increased response rate to EGFR TKIs (p < .0001) but not chemotherapy. Overall survival was significantly prolonged in EGFR mutation-positive patients (p = .001), with a median survival of 3.1 years compared with 1.6 years in mutation-negative patients, after adjusting for age, gender, and stage at diagnosis. Integrating molecular profiling into clinical care is feasible in NSCLC patients and provides useful clinical information.
Insights
Somatic mutations in the epidermal growth factor receptor (EGFR) gene predict better response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Identifying these mutations in clinical care improves patient outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Somatic mutations in the epidermal growth factor receptor (EGFR) gene are crucial biomarkers for non-small cell lung cancer (NSCLC) treatment.
- EGFR tyrosine kinase inhibitors (TKIs) have shown efficacy in NSCLC patients with specific EGFR mutations.
Purpose of the Study:
- To investigate the feasibility and clinical utility of screening for somatic EGFR mutations in NSCLC patients as part of routine clinical care.
- To analyze the association between EGFR mutation status, clinical characteristics, and treatment response to EGFR TKIs and chemotherapy.
Main Methods:
- Retrospective cohort study of 278 NSCLC patients undergoing EGFR mutation testing.
- Direct DNA sequencing of EGFR exons 18-24.
- Analysis of clinical characteristics, mutation status, treatment response, and survival data.
Main Results:
- EGFR somatic mutations were identified in 24% of patients.
- Minimal smoking history was the strongest predictor of EGFR mutations; each pack-year decreased mutation likelihood by 5%.
- EGFR mutations were associated with significantly higher response rates to EGFR TKIs (p < .0001) and prolonged overall survival (median 3.1 vs. 1.6 years, p = .001).
Conclusions:
- Integrating molecular profiling for somatic EGFR mutations into clinical care for NSCLC is feasible and provides valuable prognostic and predictive information.
- EGFR mutation status is a key determinant of treatment response and survival in NSCLC patients treated with EGFR TKIs.
